CA2980385A1 - Pericyte long non-coding rnas - Google Patents

Pericyte long non-coding rnas Download PDF

Info

Publication number
CA2980385A1
CA2980385A1 CA2980385A CA2980385A CA2980385A1 CA 2980385 A1 CA2980385 A1 CA 2980385A1 CA 2980385 A CA2980385 A CA 2980385A CA 2980385 A CA2980385 A CA 2980385A CA 2980385 A1 CA2980385 A1 CA 2980385A1
Authority
CA
Canada
Prior art keywords
lncrna
tykril
inhibitor
expression
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2980385A
Other languages
English (en)
French (fr)
Inventor
Christoph Michael ZEHENDNER
Stefanie Dimmeler
Andreas Zeiher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe Universitaet Frankfurt am Main
Original Assignee
Goethe Universitaet Frankfurt am Main
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe Universitaet Frankfurt am Main filed Critical Goethe Universitaet Frankfurt am Main
Publication of CA2980385A1 publication Critical patent/CA2980385A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2980385A 2015-03-20 2016-03-18 Pericyte long non-coding rnas Abandoned CA2980385A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102015003656 2015-03-20
DE102015003656.4 2015-03-20
PCT/EP2016/056013 WO2016150870A1 (en) 2015-03-20 2016-03-18 Pericyte long non-coding rnas

Publications (1)

Publication Number Publication Date
CA2980385A1 true CA2980385A1 (en) 2016-09-29

Family

ID=55586316

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2980385A Abandoned CA2980385A1 (en) 2015-03-20 2016-03-18 Pericyte long non-coding rnas

Country Status (5)

Country Link
US (1) US20180044672A1 (enExample)
EP (1) EP3271458A1 (enExample)
JP (1) JP2018517660A (enExample)
CA (1) CA2980385A1 (enExample)
WO (1) WO2016150870A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110699441A (zh) * 2019-06-18 2020-01-17 云南省玉溪市人民医院 一种检测骨质疏松症的生物标志物、该标志物的应用及检测方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118207257A (zh) * 2017-06-19 2024-06-18 洛桑大学 控制心肌纤维化和重塑的方法和组合物
BR112021009054A2 (pt) 2018-11-13 2021-08-24 Lipigon Pharmaceuticals Ab Oligonucleotídeos angptl4 influenciando a regulação do metabolismo de ácido graxo
CN109517049B (zh) * 2018-11-16 2021-04-13 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Linc00266-1多肽作为实体瘤标志物的应用
US10851376B2 (en) 2018-12-28 2020-12-01 The Florida International University Board Of Trustees Long noncoding RNAs in pulmonary airway inflammation
CN110403954B (zh) * 2019-07-19 2022-11-11 广东省实验动物监测所 LncRNA XLOC_110286的抑制剂在制备促进血管新生的药物中的应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN111118143B (zh) * 2020-01-16 2020-09-15 西安市红会医院 检测及靶向rp11-754b17.1的试剂及其在关节炎中的应用
CN111560427A (zh) * 2020-05-19 2020-08-21 苏州大学附属儿童医院 lncRNA作为新生儿肠外营养相关性肝病特异性标志物的应用
WO2024102894A2 (en) * 2022-11-11 2024-05-16 The Regents Of The University Of California Methods for treating monge's disease
CN117180297B (zh) * 2023-09-08 2024-09-20 广州医科大学附属第一医院（广州呼吸中心） 用于前列腺癌诊断、治疗以及预后评估的标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
MX2009011226A (es) 2007-04-17 2010-04-01 Imclone Llc Inhibidores especificos pdgfrbeta.
EP2604279A1 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
US20150018404A1 (en) * 2011-08-03 2015-01-15 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide compounds for treating hearing and balance disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110699441A (zh) * 2019-06-18 2020-01-17 云南省玉溪市人民医院 一种检测骨质疏松症的生物标志物、该标志物的应用及检测方法

Also Published As

Publication number Publication date
JP2018517660A (ja) 2018-07-05
WO2016150870A1 (en) 2016-09-29
US20180044672A1 (en) 2018-02-15
EP3271458A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
US20180044672A1 (en) Pericyte Long Non-Coding RNAs
Wei et al. Long non-coding RNA AK038897 aggravates cerebral ischemia/reperfusion injury via acting as a ceRNA for miR-26a-5p to target DAPK1
CN107108685B (zh) miR-29模拟物及其用途
JP6621409B2 (ja) Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
EP3054017A1 (en) Circular RNA for the diagnosis and treatment of cardiovascular diseases
Hu et al. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells
US20180023080A1 (en) Long Non-Coding RNA For The Treatment Of Endothelial Dysfunction
US11912994B2 (en) Methods for reactivating genes on the inactive X chromosome
JP2015518714A (ja) 遺伝子発現を調節するための組成物及び方法
Yuan et al. miR-770–5p inhibits the activation of pulmonary fibroblasts and silica-induced pulmonary fibrosis through targeting TGFBR1
US20240117358A1 (en) Methods and compositions for diagnosing and treating prostate cancer based on long noncoding rna overlapping the lck gene that regulates prostate cancer cell growth
Hou et al. MicroRNA-188-5p regulates contribution of bone marrow-derived cells to choroidal neovascularization development by targeting MMP-2/13
WO2013165320A1 (en) Treating cancer by increasing expression of socs6
US9075064B2 (en) Method for decreasing radioresistance and growth, metastasis and infiltration of cancer cells through regulating expression or activity of TM4SF4 in non-small cell lung cancer
CA3107700A1 (en) Compositions comprising intermediate non-coding rna regulators modulating the expression of etv6 or foxo1 and uses thereof
Cheng et al. Rapamycin-induced modulation of miRNA expression is associated with amelioration of HIV-associated nephropathy (HIVAN)
KR20230004456A (ko) 면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물
CN105779576A (zh) 人tnfrsf12a基因的用途及其相关药物
US20190381125A1 (en) Methods of Treating Angiogenesis-Related Disorders Using JNK3 Inhibitors
Pervushin et al. Mechanisms and Ways to Overcome Acquired Resistance of Cancer Cells to Mcl-1 Antagonists
Oltra et al. miR‑205: A dual regulator of angiogenesis in health and disease
Wang et al. LncRNA DANCR Activates p38/mTOR‐Mediated Autophagy via ANXA2 to Exacerbate Oxygen‐Induced Retinal Neovascularization in Mice
Li et al. MiR‐30d‐5p Regulates Bone Remodeling and Vessel Remodeling in Osteoporosis by Targeting GRP78
WO2024003350A1 (en) Combination therapy for melanoma
JP6320752B2 (ja) 新規ユビキチンリガーゼ及びその利用方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220608

FZDE Discontinued

Effective date: 20220608

FZDE Discontinued

Effective date: 20220608